未登录

S

Sean Khozin

MIT

H指数:33

被引数:5,350

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Towards a framework for a new research ecosystem

构建一个新研究生态系统的框架

humanities social sciences communications

IF0

2025-07-080

OA

Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank

真实世界证据在乳腺癌治疗决策中的可接受性与使用情况：来自多学科智库的行动倡议

ADVANCES IN THERAPY

IF4

2025-05-120

OA

From organs to algorithms: Redefining cancer classification in the age of artificial intelligence

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-08-291

OA

Real-world evidence for regulatory decision-making: updated guidance from around the world

监管决策的真实世界证据: 来自世界各地的最新指南

FRONTIERS IN MEDICINE

IF3

2023-10-3013

OAAI

A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

IF8.3

2022-11-010

PRE

The design and evaluation of hybrid controlled trials that leverage external data and randomization

NATURE COMMUNICATIONS

IF15.7

2022-10-027

OAAI

A digital highway for data fluidity and data equity in precision medicine

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

IF8.3

2021-08-014

PREAI

Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer

JCO CLINICAL CANCER INFORMATICS

IF2.8

2020-11-011

OAAI

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

BRITISH JOURNAL OF CANCER

IF6.8

2020-09-0154

OAAI

Author's Response to A Letter in Support of Real-World RECIST

ADVANCES IN THERAPY

IF4

2020-02-130

OAAI

Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2019-09-2418

OAAI

Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer

IF5.1

2019-08-05110

OAAI

Artificial intelligence and machine learning in clinical development: a translational perspective

NPJ DIGITAL MEDICINE

IF15.1

2019-07-26253

OAAI

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

ADVANCES IN THERAPY

IF4

2019-05-28125

OAAI

Developing and adopting safe and effective digital biomarkers to improve patient outcomes (vol 2, 14, 2019)

NPJ DIGITAL MEDICINE

IF15.1

2019-05-109

OAAI

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer

ANNALS OF ONCOLOGY

IF65.4

2019-05-01111

OAAI

Decentralized Trials in the Age of Real-World Evidence and Inclusivity in Clinical Investigations

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-04-2373

PREAI

Developing and adopting safe and effective digital biomarkers to improve patient outcomes

开发和采用安全有效的数字生物标志物来改善患者的治疗效果

NPJ DIGITAL MEDICINE

IF15.1

2019-03-11172

OAAI

Time to treatment discontinuation as a pragmatic endpoint: A US Food and Drug Administration pooled analysis of CDK 4/6 inhibitors

CANCER RESEARCH

IF16.6

2019-02-151

PRE

Assessing function of electronic health records for real-world data generation

BMJ EVIDENCE-BASED MEDICINE

IF7.6

2018-11-2611

PREAI